Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal acwy conjugate vaccine (Sanofi)
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The meningococcal ACWY conjugate vaccine is an inactivated subunit (conjugate) vaccine that protects against invasive disease caused by Neisseria meningitidis serogroups A, C, W, and Y. It works by presenting polysaccharide antigens from the bacterial capsule—specifically from groups A, C, W-135 (W), and Y—conjugated to a carrier protein (such as diphtheria toxoid or CRM197). This enhances immunogenicity by stimulating a T-cell dependent immune response. The primary indication is prevention of invasive meningococcal disease including bacterial meningitis and septicemia. The vaccines are recommended for adolescents as part of routine immunization schedules and for individuals at increased risk due to medical conditions or exposure risks. Major brands include Menactra (Sanofi), Menveo (GSK; originally Novartis), and MenQuadfi (Sanofi)[3][5][8].
- Brand names
- MenactraMenveoMenQuadfi
- Other names
- menacwy vaccinemeningitis acwy vaccinequadrivalent meningococcal conjugate vaccine
02
Targets
Neisseria meningitidis group C capsular polysaccharideNmA CPS (Neisseria meningitidis group A capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal acwy conjugate vaccine (Sanofi).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal acwy conjugate vaccine (Sanofi).